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Salvianolic acid B (Sal B), a pure water-soluble compound extracted from Radix Salviae miltiorrhizae, has been reported to
possess potential cardioprotective eﬃcacy. To identify proteins or pathways by which Sal B might exert its protective activities
on the cardiovascular system, two-dimensional gel electrophoresis-based comparative proteomics was performed, and proteins
altered in their expression level after Sal B treatment were identiﬁed by MALDI-TOF MS/MS. Human umbilical vein endothelial
cells (HUVECs) were incubated at Sal B concentrations that can be reached in human plasma by pharmacological intervention.
Resultsindicatedthatcaldesmon,anactin-stabilizingprotein,wasdownregulatedinSalB-exposedHUVECs.Proteinsthatshowed
increased expression levels upon Sal B treatment were vimentin, T-complex protein 1, protein disulﬁde isomerase, tropomyosin
alpha, heat shock protein beta-1, UBX domain-containing protein 1, alpha enolase, and peroxiredoxin-2. Additionally, Sal B leads
to increased phosphorylation of nucleophosmin in a dose-dependent manner and promotes proliferation of HUVECs. We found
that Sal B exhibited a coordinated regulation of enzymes and proteins involved in cytoskeletal reorganization, oxidative stress, and
cell growth. Our investigation would provide understanding to the endothelium protection information of Sal B.
1.Introduction
Traditional Chinese medicine (TCM) has been widely prac-
ticed for thousands of years in China and Eastern Asia.
TCM is now an integrated part of the healthcare system
in that part of the world, and currently in China a strong
push to modernize TCM through both scientiﬁc research
and industrial development is underway. Radix Salviae
miltiorrhizae (Danshen) has been used for the treatment of
cardiovascular disorders and cerebrovascular diseases [1–4].
Salvianolic acid B (Sal B), a pure water-soluble compound
extracted from Danshen, has been reported to possess many
biological activities attributed to the whole-plant Danshen
herb, such as sedative, antioxidant, hepatoprotective and
antiﬁbrogenic eﬀects [5], inhibition of platelet aggregation,
improvement of coronary microcirculation and cerebral
blood ﬂow [6], enhancement of angiogenic processes, and
protection against injury to the heart and brain caused
by ischemia reperfusion [7]. Following pretreatment with
diﬀerent dosages (0.0125–0.5mg/mL) of Sal B for various
times (2–36h) followed by a 24h incubation, Shi et al.
demonstrated that Sal B upregulate the expression of tissue-
type plasminogen activator (t-PA) and thrombomodulin
(TM) and downregulate the expression of PAI-1 [8]. Our
previous data also indicated that Sal B helps maintain the
integrity of the endothelium by exerting anticoagulation
and proﬁbrinolytic eﬀects in primary human umbilical vein
endothelial cells (HUVECs).
In the past decades in Europe, the US, and other parts
of the world, we have witnessed an increasing interest in
the use of Sal B to formulate drugs, dietary supplements,
and functional food products [9]. In the current study, we2 Evidence-Based Complementary and Alternative Medicine
aimed to investigate the modes of actions of Sal B for the
prevention of vascular diseases. A previous study reported
an HPLC method for the determination of Sal B in rat
plasma after oral administration of Danshen extract and
the pharmacokinetics of Sal B were investigated. The results
showed the concentration of Sal B in rat plasma over a
concentration range of 10.8–259.4μg/mL [10]. The Sal B
concentration of 125μg/mL that was predominantly used in
this current study was intended to be clinically relevant. To
identify proteins or pathways by which Sal B might exert
its protective activities on the cardiovascular system, we
surveyed global changes in proteins after Sal B treatment in
HUVECs. We report here our initial ﬁndings of Sal B on the
protein expression in HUVECs based on the well-established
2Dgel/MALDI-TOF/TOFmassspectrometeranalyses.Then,
thediﬀerentialexpressionofsomeproteinswasconﬁrmedby
Western blot.
2.MaterialsandMethods
2.1. Cell Culture. HUVECs purchased from Bioresource Col-
lectionandResearchCentre,Hsinchu,Taiwanwereculturedin
medium M-199 (Gibco BRL, Grand Island, NY, USA), sup-
plemented with 10% fetal bovine serum (Gibco BRL, Grand
Island, NY, USA), 1% endothelial cell growth supplement
(Upstate Biotechnology, Lake Placid, NY, USA), 10U/ml
heparin, 100U/ml penicillin, and 100μg/ml streptomycin
(Gibco BRL, Grand Island, NY, USA). HUVECs of fourth
to seventh passage were grown to conﬂuence, then were
trypsinized, suspended, and seeded into culture dishes or
wells for experimental use.
2.2. Sample Preparation for 2-DE. Endothelial cells (1×106
cells/dish) in 6cm plate cultivated for 16h were treated
with 125μg/mL of Sal B (Ivy Fine Chemicals, NJ, USA)
in M199 containing 0.1% FBS for 12h. After additional
24h incubation, cells were suspended in a lysis buﬀer (8M
urea, 4% CHAPS, 40mM Tris, 12.5mM DTT, and 0.5%
carrier ampholytes). Cell lysate was sonicated on ice for
approximately 2min and centrifuged to remove debris. The
protein concentration was assayed using a 2D quantiﬁcation
kit (Amersham Bioscience, Piscataway, NJ).
2.3. 2-DE. The ﬁrst dimensional isoelectric focusing (IEF)
w a sp e r f o r m e do np r e c a s t1 3 c mi m m o b i l i z e dp H4t o
7 nonlinear gradient (IPG) strip (Amersham Bioscience,
Piscataway, NJ) at 20
◦C with a maximum current setting
of 40μA/strip using an Amersham Pharmacia IPGphor IEF
unit. Protein (100μg) was added to rehydration solution
(7M urea, 2M thiourea, 4% CHAPS, 0.2% DTT, 0.5%
Triton X-100, and 0.4% carrier ampholytes). Strips were
rehydrated for 12h, and then IEF was performed for a total
of 45,000Vh. Following IEF separation, the gel strip was ﬁrst
equilibrated for 15min in the equilibration buﬀer consisting
of 50mM Tris-HCl pH 8.8, 6M Urea, 30% glycerol, 2% SDS,
and 2% DTE. Then the strip was equilibrated for another
15min in the same equilibration buﬀer, except that DTE
was replaced with 2.5% w/v iodoacetamide. Sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE) (10%) was applied
for the second-dimension electrophoresis. After the second
dimension,gelwassilverstainedaccordingtomanufacturer’s
instruction (Amersham Bioscience, Piscataway, NJ). Tripli-
cate electrophoresis was performed for each pair of protein
sample (control and Sal B treated) from three independent
experiments to ensure reproducibility.
2.4. Image Acquisition and Analysis. The silver-stained 2-DE
gel was digitally scanned as 2-DE image on the Typhoon
9200 ﬂuorescence image scanner (amersham bioscience, Pis-
cataway, NJ). Spot detection, quantiﬁcation, and matching
were managed using the ImageMaster software (amersham
bioscience, Piscataway, NJ). The theoretical Mr and pI values
of the 2-DE markers were used to calibrate the Mr and pI
of the protein spots in the 2-DE gels. Protein spots with
twofold or more increased or decreased intensity between
control and Sal B-treated groups with P<. 05 (Student’s t-
test) were considered as signiﬁcantly diﬀerentially expressed
proteins. The protein spots were cut from the gels and used
for MALDI-TOF MS/MS identiﬁcation.
2.5. Tryptic In-Gel Digestion of 2-DE-Resolved Proteins.
Protein spots were excised from the 2-DE gel and soaked in
25mM ammonium bicarbonate (pH 8.5)/50 % acetonitrile
at room temperature for 15min. Following three washes
with the above buﬀer, the gel pieces were dehydrated in
100% acetonitrile for 5min and dried for 5min in a speed-
vac centrifuge. The gel pieces were swollen and crashed
in 25mM ammonium bicarbonate buﬀer containing 30ng
trypsin and incubated at 37◦C for at least 16hr. Peptide
mixtures were extracted twice with 50% acetonitrile/5%
triﬂuoroaceticacid(TFA)byoccasionalsonicationanddried
in a speed-vac concentrator. After dissolved in 0.1% TFA,
the peptide mixtures were puriﬁed by using C18 Zip-Tip
(Millipore Corporation, Billerica, MA, USA).
2.6. MALDI-TOF/TOF Mass Spectrometry and Protein Iden-
tiﬁcation. Mass analyses were performed using a MALDI-
TOF/TOF mass spectrometer (Ultraﬂex, Bruker Dalton-
ics, Billerica, MA). Peptide mixtures were spotted onto
the MALDI target plate using a saturated matrix solu-
tion of α-cyano-4-hydroxycinnamic acid (Sigma) in 80%
acetonitrile/1% TFA. The instrument was externally cali-
brated with standard peptide mixtures and further adjusted
with the lock mass feature using adrenocorticotropic hor-
mone (ACTH) as the near-point calibration agent. Mass
spectra were acquired for the mass range of 700–3000Da
and automatically processed by the Biotool Data Analysis
software (Bruker Daltonics, Billerica, MA) and MASCOT
software (Matrix Science, MA) for PMF searches against
the SWISS-Prot database. The search parameters allowed
for oxidation of methionine, N-terminal acetylation, and
carboxyamidomethylation of cysteine. The criteria for pos-
itive identiﬁcation of proteins were set as follows: (i) at
least ﬁve matching peptide masses, (ii) 50ppm or better
mass accuracy, (iii) one incomplete cleavage tolerance, (iv)
limiting the search to the human subset of the database andEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: Silver-stained 2-DE gel of proteins extracted from Sal B-treated (a) and control (b) HUVECs. 100μg of total protein was subjected
in linear IPG strips, with a pH range of 4 to 7, followed by 10% SDS-polyacrylamide gel electrophoresis. Molecular mass and p markers are
indicated along the gels.
(v) molecular weight and PI of identiﬁed proteins should
match the estimated values obtained from image analysis.
2.7. Electrophoresis and Immunoblot Analysis. HUVECs
treated with Sal B or not were washed twice with cold
phosphate-buﬀered saline (PBS), lysed in PBS containing
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium
dodecylsulfate(SDS),5μg/mLaprotinin,100μg/mLphenyl-
methylsulfonyl ﬂuoride, 1μg/mL pepstatin A, and 1mM
ethylenediaminetetraacetic acid at 4◦C for 20min, and then
disrupted with a needle. Total lysates were quantiﬁed using
a micro-BCA kit (Thermo Fisher Scientiﬁc, Rockford, IL,
USA). Proteins (50μg) were resolved by SDS-polyacrylamide
gel electrophoresis and transferred electrophoretically to a
PVDF ﬁlter. The nylon ﬁlter was blocked for 1h in 5% fat-
free milk in PBST buﬀer (PBS with 0. 05% Tween-20). After
a brief wash in PBST buﬀer, the nylon ﬁlter was incubated
overnight at 4◦C with antibodies (mouse antihuman TM
antibody (1:1000), mouse antihuman nucleophosmin anti-
body (1:1000), and mouse antihuman caldesmon antibody
(1:1000), Santa Cruz Biotech, Santa Cruz, CA, USA), mouse
antihuman vimentin antibody (1:1000), mouse antihu-
man T199 phosphonucleophosmin antibody (1:1000), and
mouse antihuman α-tubulin antibody (1:2000) (Abcam,
Cambridge Science Park, Cambridge, UK) diluted in PBST
buﬀer.Theprimaryantibody wasremoved,andtheﬁlterwas
washed extensively in PBST buﬀer. Subsequent incubation
with goat anti-mouse antibody (1:10000) conjugated with
horseradishperoxidase(SantaCruzBiotech,SantaCruz,CA,
USA) proceeded at room temperature for 2h. The ﬁlter was
washed extensively in PBST buﬀer to remove the secondary
antibody, and the blot was visualized with ECL reagent.
Analysis of band densities was accomplished with ImageJ gel
analysis software.
2.8. Proliferation Assay. HUVECs (7.5 × 104 per well) were
treatedwithorwithoutSalB(125μg/mL)for12h.Cellswere
quantiﬁed with a cell proliferation assay kit by using a 4,5-
dimethylthiazol-3-carboxymethoxy-phenyl-4-sulfophenyl-
tetrazolium (MTS) tetrazolium compound (Promega).
2.9. Statistical Analysis. All cellular experiments were per-
formed at least 3 times. Data are expressed as the mean
± SD. Statistical analysis of the data was compared using
the unpaired Student’s t-test. Diﬀerences were considered as
statistically signiﬁcant at P<. 05.
3. Results
3.1. 2-DE of Sal B-Treated HUVECs and Identiﬁcation of
Diﬀerentially Expressed Proteins. From our previous report,
Sal B was shown to increase the ﬁbrinolytic and antico-
agulant potential of cultured HUVECs by upregulating the
expression of t-PA and TM and by downregulating the
expression of PAI-1 in a dose-dependent manner following a
12h pretreatment [8]. To investigate the other target-related
proteins of Sal B in HUVECs, protein proﬁles of control
and Sal B-treated HUVECs were studied by comparative
proteomic analysis. Representative 2-DE gel images for
controlandSalB-treatedHUVECsareshowninFigure 1.U p
to 650 protein spots could be resolved from each gel. Nine
upregulated protein spots and one downregulated protein
spot in the Sal B-treated group compared with control were
found. The ten diﬀerentially expressed proteins are indicated
by arrows (Figure 1). The signiﬁcance of the changes in
protein abundance was calculated by Student’s t-test. For
all the selected spots, the P values between the control and
Sal B-treated groups were less than .05. The fold diﬀerence
indicated the ratio of the intensity value of the Sal B-treated4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: MALDI TOF/TOF MS/MS spectra of caldesmon isolated from a 2-DE gel. Out of 11 representative spectra, two peptides were
matched and listed.
group relative to the value of control group. Notably, spots 3
and 8 were found only in the Sal B-treated group.
The diﬀerentially expressed protein spots were isolated
from the 2-DE gel and subjected to trypsin digestion and
identiﬁed using MALDI TOF/TOF mass spectrometry. The
peptide mass peaks and peptide sequences were compared
with those in the Swiss-Prot database. The MALDI-TOF
MS/MS analysis result of caldesmon (CaD) is shown in
Figure 2 as an example. The complete list of proteins
identiﬁed unambiguously and the MALDI-TOF MS/MS
analysis results are presented in Table 1. The Swiss-Prot
accession number, theoretical molecular weight and pI of
each protein spot, and the protein scores are also included.
Furthermore, the reported localization and the biological
function of the proteins are also listed. The altered pro-
teins induced by Sal B treatment were categorized into
several groups according to their putative/known functions.
The major group of altered proteins was related to the
cytoskeleton, including an increase in vimentin, T-complex
protein 1β, and tropomyosin as well as the downregulation
of caldesmon.
3.2. Western Blot Analysis. The caldesmon, vimentin, and
nucleophosmin (NPM) proteins were selected and subjected
to Western blot analysis (Figure 3(a)). Compared with the
control group, the level of caldesmon in the Sal B-treated
group decreased, whereas the level of vimentin increased
1.4-fold after that treatment. Note that HUVECs expressed
two isoforms of vimentin, a higher-molecular-mass form
(experimental MW of 57kDa) and a lower-molecular-mass
form (experimental MW of 48kDa), are both present in
control and in Sal B-treated cells. The immunoblot data
conﬁrmed the 2-DE gel data. It has been found that protein
expression levels of nucleophosmin are increased in 2D gel,
whereas the Westernblot experiment using the anti-NPM
antibody indicated that the total protein content of NPM
did not change after Sal B treatment, since the diﬀerential
protein spots showed electrophoretic mobility variation and
moved to a more acidic position on the gel, which may be
resulted from Sal B-mediated modiﬁcation through post-
translational phosphorylation of NPM. NPM was identiﬁed
as a phosphoprotein, and several amino acid residues of this
protein were identiﬁed as phosphorylation consensus sites.
Among them, threonine 199 (Thr199) has been shown to
be phosphorylated by cyclin E-cyclin-dependent kinase 2
(cyclin E/cdk2) during mitosis [11]. We therefore analyzed
the phosphorylation of NPM by Western blot with an
antibody speciﬁc for Thr199 phospho-NPM. Compared with
the control group, the level of phospho-NPM in the Sal B-
treated group increased to about 1.5-fold, which indicated
that Sal B treatment induced progressive phosphorylation
modiﬁcation of NPM. We therefore examined the mitogenic
eﬀects of Sal B on HUVEC (Figure 3(b)). Sal B treatment
resultedinanincreasedcellviabilityupto25%ofthecontrol
value.Evidence-Based Complementary and Alternative Medicine 5
Table 1: Identiﬁed proteins that were changed in Sal B-treated HUVEC.
Spot
no. Protein identity SwissProt
no.
Relative spot
intensity %
(Sal B/control,
100%)
pI/Mr Mascot
score Cellular location Molecular function
1 Caldesmon Q05682 45% 5.5/93.3 81 Cytoskeleton Actin binding, calmodulin binding,
myosin binding, tropomyosin binding
2 Vimentin P08670 227% 4.9/53.7 129 Cytoplasm intermediate
ﬁlament
Protein binding, structural
c o n s t i t u e n to fc y t o s k e l e t o n
3 T-complex protein
1 subunit beta P78371 Sal B only 6/57.8 223 Nucleus ATP binding, unfolded protein
binding
4
Protein disulﬁde-
isomerase
A3
P30101 260% 5.9/57.1 180 Endoplasmic reticulum
melanosome
Cysteine-type endopeptidase activity,
phospholipase C activity protein
disulﬁde isomerase activity
5 Nucleophosmin P06748 Sal B only 4.5/32.7 67 Nucleus, nucleoplasm,
spindle pore cetrosome
6 Heat shock protein
beta-1 P04792 230% 6/22.8 135 Cell surface, cytoplasm
nucleus Identical protein binding
7 Tropomyosin
alpha-3 chain P06753 Only Sal B 4.5/32.9 85 Muscle thin ﬁlament
tropomyosin Actin binding
8
UBX domain-
containing protein
1
Q04323 316% 5.1/33.4 153 Cytoplasm ATPase binding, polyubiquitin
binding
9 Alpha-enolase P06733 237% 7.7/47.5 127 Nucleus, plasma
membrane
Magnesium ion binding, serine-type
endopeptidase activity,
phosphopyruvate hydratase
activity, transcription factor activity
10 Peroxiredoxin-2 P32119 258% 5.6/22 140 Cytoplasm Thioredoxin peroxidase activity
We next evaluated the time course eﬀects of Sal B-
regulated expression of NPM, caldesmon, and TM in
HUVECs. Expression levels of TM were elevated with
increasing the Sal B incubation time at 12h, which peaked
by 24h after stimulation (Figure 4(a)). To directly conﬁrm
the critical role of NPM, we measured the level of NPM
phosphorylation at Thr199 in response to Sal B. As shown
in Figure 4, treatment of HUVECs with Sal B resulted
in a time-dependent phosphorylation of NPM at Thr199.
Furthermore, increasing Sal B incubation time resulted in
decreased expression of caldesmon to about 70% compared
with the control. Moreover, the earlier studies on Sal B
by Wang et al. showed that 10μM (7.18μg / m L )o fS a lB
can prevent epithelial-to-mesenchymal transition (EMT)
triggered by TGF-β1[ 12]. The dose-response relationships
of TM, caldesmon, vimentin, and NPM, with respect to
the low-dose ranges of Sal B treatment, were illustrated
to conﬁrm the protein proﬁle change. HUVECs were
pretreated with vehicle or increasing concentrations (6.25–
25μg/mL) of Sal B for 12h. When the concentration of
Sal B was reduced to 6.25μg/mL, expression of TM was
maintained at a constant level with minor decrease, whereas
dose-dependent increase in TM was observed between the
concentrations of 12.5 to 25μg/mL of Sal B. Additionally,
after treated with Sal B at the concentrations of 6.25, 12.5,
25μg/mL, caldesmon levels were decreased proportionally
to the Sal B exposure, which was about 45% of control
level by administration of 25μg/mL of Sal B. It appeared
that Sal B treatment caused a concentration-dependent
enhancement of vimentin at concentrations ranging from
6.25μg/mL to 25μg/mL. We further investigated the eﬀect of
Sal B on the phosphorylation of NPM. Sal B began to induce
NPM phosphorylation at 6.25μg/mL and continued in a
dose-dependent manner (Figure 4(b)). Our results strongly
suggest that Sal B treatment aﬀects the protein proﬁle and in
a concentration-dependent manner on HUVECs.
4. Discussion
Danshen is one of the oldest herbs oﬃcially listed in the tra-
ditionalChinesePharmacopoeiaandisusedinthetreatment
of myocardial infarction and other cardiac symptoms [3, 4,
13]. As a major constituent of Danshen, the action proﬁle of
Sal B on HUVECs has not been well documented. This study
comparedwhole-cellproteinsfromHUVECstreatedwithSal
B to controls via a proteomic method that involved fraction-
ation of proteins by 2-DE and identiﬁcation of diﬀerentiated
proteins by MALDI TOF MS/MS. We identiﬁed 10 protein
spots that were involved in several biological pathways.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Sal B treatment decreased caldesmon expression and increased vimentin and phospho-NPM expression. (a) Cell lysates (50μg)
were processed for Western blot analysis using monoclonal antibodies against TM and α-tubulin. The relative expression of caldesmon,
vimentin, and NPM was quantiﬁed by densitometry and normalized to α-tubulin. Phospho-NPM was quantiﬁed by densitometry and
normalized to the NPM protein. Control values were set to one. (b) Mitogenic eﬀe c to fS a lBo nH U V E C sp r o l i f e r a t i o n .H U V E C sw e r e
seeded (7.5 × 104 cells/well in 96-well tissue culture plate) and pretreated with Sal B for 12h. The cells were washed and maintained in
fresh EBM containing 0.25% FBS for additional 24h incubation at 37◦C. The cell viability was measured by the metabolic activity of viable
cells with the Cell Proliferation Reagent WST-1. The values are presented as means of cell count obtained from six wells for each treatment.
∗P<. 05 as compared with control as determined by analysis of variance followed by an unpaired Student’s t-test.
Although we found the proteomics-based approach to be
valuable in generating novel information, 2-DE bears some
limitations in identifying low-abundance proteins. Due to
these limitations, it is clear to understand that previously
characteristicproteinssuchasTMandPAI-1werenotreadily
detected in our analysis.
Maintaining the integrity and function of the endothelial
barrier is critical to vessel physiology. Those drugs and fac-
tors known to favorably inﬂuence endothelial cell function
and promote angiogenesis have been shown to promote
reendothelialization after vascular injury. We speculate that
Sal B was able to induce an acceleration of the endothelial
cellproliferationtoreﬁllanadequatecelldensity.Thepresent
investigation shows that Sal B induced phosphorylation of
NPM. NPM has been reported to play a complex role
in proliferation [14], apoptosis [15–17], and cell cycle
progression [18]. It has also been postulated that NPM
enhances proliferation by stimulating ribosome synthesis
or DNA polymerase activity [19]. Previous studies have
shown that human NPM is bound to unreplicated cen-
trosomes in late G1 phase and undergoes phosphorylation
by cyclin E/cdk2 at Thr199, prompting NPM’s dissociation
from the centrosome and subsequent duplication [20].
Other groups have provided evidence that induction of
NPM protein expression is the critical limiting factor in
N P M ’ sa b i l i t yt op r o m o t ec e l lg r o w t ha n dp r o l i f e r a t i o n
[21, 22]. However, independent groups have demonstrated
the roles of NPM, and its phosphorylation at Thr199 in
the process of centrosome duplication does not account
for the observed increase in cell growth and proliferation
[23]. Salvianolic acid B stimulates the proliferation and tube
formation of a murine simian virus resistance endothelial
cell line through the sequential upregulation of the genes
encoding MMP-2, VEGF, VEGF receptor 2, and Tie-1 [24].Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: Western blot analysis of caldesmon, phospho-NPM, and vimentin expression after Sal B treatment. (a) HUVECs were pretreated
with 125μg/mL of Sal B for 12h. The cells were washed and maintained in fresh M199 medium for an additional 12 or 24h incubation at
37◦C. The expression levels of caldesmon, phospho-NPM, and vimentin were assayed. Total tubulin is shown as loading control. These data
arerepresentativeresultsfromthreeexperiments.Therelativeamountsofcaldesmonandvimentin,comparedtototaltubulin,andphospho-
NPM normalized to the NPM were calculated, and the values represented the mean of triplicate experiments ± standard deviations. Control
valuesweresetto100%. ∗P<. 05versuscontrol.Thebottompanelsshowthatthedensitiesofbandsquantiﬁedbydensitometry(b)HUVECs
were pretreated with Sal B at the concentrations of 6.25, 12.5, or 25μg/mL for 12h. Cells were then washed and maintained in fresh M199
for an additionally 24h incubation at 37◦C. Dose eﬀects of Sal B on the expression of TM, caldesmon, vimentin, and phospho-NPM protein
on HUVECs were demonstrated by Western blot. The tubulin or nucleophosmin was used as normalized control as described above. These
data are representative results from three experiments. The bottom panels show the densities of bands analyzed by using the NIH software
program ImageJ. ∗P<. 05 versus control.
To date, phosphorylation of NPM-Thr199 continues to be the
subject of discussion and debate in the ﬁeld. To investigate
NPM’s contribution to Sal B’s protective eﬀect, we tried to
knockdown endogenous NPM, which resulted in HUVECs
undergoing apoptosis (data not shown). Since NPM is
considered as an antiapoptotic protein [17, 25], absence of
NPM resulted in a dramatic loss of viability of HUVECs.
Our results demonstrate that NPM plays an essential role
in HUVECs and that Sal B may exert its potential protective
eﬀects by partially modulating NPM activity.8 Evidence-Based Complementary and Alternative Medicine
The low molecular weight isoform of caldesmon, l-
CaD, is an actin-binding protein preferentially expressed in
nonmuscle cells [26]. In several studies, l-CaD is described
as a determinant factor in the organization and stabilization
of the microﬁlament network in nonmuscle tissues and cells
[27, 28]. Moreover, the cytostatic and proapoptotic potential
of l-CaD revealed that it could regulate endothelial cell
growth and survival via the modulation of cell shape and the
cytoskeleton [29]. In our proteomics analysis, we found that
Sal B decreased the expression of l-CaD, and this might aﬀect
cytoskeleton rearrangements, assembly of focal adhesions,
and/or progression of HUVEC growth. This is consistent
with previously ﬁnding that Sal B demonstrates enhancing
eﬀects on endothelial cell growth and diﬀerentiation.
Besides caldesmon, intermediate ﬁlament vimentin is
the other cytoskeleton protein which is modulated by Sal
B. Endothelial cells contain an extensive interconnecting
cytoplasmic network of vimentin. Vimentin is upregulated
in migratory endothelial cells compared to nonmigrating
endothelialcells[30].Severalphysiologicalrolesforvimentin
have been proposed, including determination and main-
tenance of cell shape, transmission of mechanical stress,
and the targeting of molecules between the nucleus and
cytoplasm [31]. The cortex mesh of vascular endothelial
cells consists of intertwined actin and vimentin [32]. It is
noteworthy that in vitro vimentin synthesis is characteristic
of proliferating cells [33]. The observed changes in vimentin
expressionsuggestedapossibleroleforSalBinthetransition
of endothelial cells towards migrating and proliferating
phenotypes. Interestingly, T-complex protein 1 (TCP-1) was
also upregulated in Sal B-stimulated endothelial cells, and
thisproteinisamemberofthecytosolicchaperonincomplex
in eukaryotic cells [34]. TCP-1 containing chaperonins
are nucleotide, actin, and tubulin binding proteins. Their
expression, together with upregulation of other structural
proteins such as vimentin and tropomyosin, suggest that
changes in the concentration of these structural proteins
may account for the proliferating/migration phenotype of
endothelial cells under Sal B stimulation [28].
Peroxiredoxins, which are involved in intracellular redox
balance and have stress-speciﬁc roles in stress resistance [35],
are thioredoxin-dependent peroxide reductases localized
either in the cytoplasm (PDX 1 and PDX 2) or mitochondria
(PDX3) [36]. They represent a defense system against
reactive oxygen species, and their peroxidase activity relies
on thioredoxin. In addition, peroxiredoxin enzymes might
participate in signaling cascades. This ﬁnding indicates the
importance of antioxidant enzymes during the pretreatment
of Sal B. These data suggested that the pharmacological
potential of Sal B against pathological processes may be
related to oxidative stress [37, 38].
In summary, Sal B treatment could change the levels
of ten proteins that play important roles in protecting
human endothelial cells via their eﬀects on oxidative stress,
cytoskeleton structure, and other processes. These observed
changes in protein expression proﬁles translate into func-
tional alternation and structure/morphological changes that
might be necessary for the vascular protective eﬀects of Sal
B. Certainly, the identiﬁed proteins might not be the only
targets of Sal B. Further studies in an eﬀort to ﬁnd other
targets as well as functional characterization of proteins
speciﬁcally regulated by Sal B will have an impact on
treatments for improving of endothelial function.
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